Journal of Clinical & Experimental Dermatology Research
Open Access
ISSN: 2155-9554
+44 1478 350008
ISSN: 2155-9554
+44 1478 350008
Richard I. Horowitz
Hudson Valley Healing Arts Center,
4232 Albany Post Road, Hyde Park, New York 12538
Tanzania
Research Article
The Use of Dapsone as a Novel “Persister” Drug in the Treatment of Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome
Author(s): Richard I. Horowitz and Phyllis R. FreemanRichard I. Horowitz and Phyllis R. Freeman
Dapsone (diaminodiphenyl sulfone, i.e., DDS) is commonly used to treat dermatological conditions including acne, dermatitis herpetiformis, and leprosy. Mycobacterium leprae, a known "persister" bacteria, requires long-term treatment with intracellular medications including rifampin and Dapsone. Other "persister" bacteria recently have been identified, including Borrelia burgdorferi, the agent of Lyme disease.
Objectives: We tested the efficacy of DDS in patients with chronic Lyme disease/PTLDS with tick-borne coinfections including Babesiosis, who failed commonly used antibiotic and antimalarial protocols.
Methods: 100 patients with Lyme disease, 56 of who were Babesia positive, were placed on Dapsone and folic acid in combination with either one or two other intracellular drugs, including rifampin, tetracycl.. View More»
DOI:
10.4172/2155-9554.1000345